Search for: "CELGENE"
Results 61 - 80
of 183
Sorted by Relevance
|
Sort by Date
1 Aug 2019, 8:34 pm
” In Celgene Corporation v. [read post]
21 Apr 2023, 9:27 am
Celgene also asserted U. [read post]
27 Sep 2015, 10:00 pm
Celgene Corp. had filed motions for sanctions in IPRs brought against its patents relating to Thalomid® (thalidomide) and Revlamid®... [read post]
27 Jul 2017, 2:42 pm
Celgene Corp., a New Jersey pharmaceutical manufacturer, has agreed to pay $280 million to settle a False Claims Act lawsuit… The post Pharmaceutical Manufacturer Agrees to Pay $280 Million to Settle Healthcare Whistleblower Lawsuit appeared first on TZ Legal - Fraud Fighters. [read post]
27 Sep 2015, 10:00 pm
Celgene Corp. had filed motions for sanctions in IPRs brought against its patents relating to Thalomid® (thalidomide) and Revlamid®... [read post]
6 Aug 2019, 10:00 pm
” In Celgene Corp. v. [read post]
23 Apr 2020, 7:18 am
Celgene’s situation is analogous. [read post]
17 Jan 2007, 1:23 pm
Thalomid was Celgene's top-selling drug last year, with sales of about $388 million. [read post]
15 Aug 2019, 10:00 am
In CELGENE CORPORATION v. [read post]
4 Feb 2010, 9:50 pm
Between 2004 and 2007, Celgene (as the patent owner) and... [read post]
17 Apr 2014, 8:07 am
Celgene Corporation, C.A. [read post]
23 Apr 2015, 1:21 pm
On April 23, 2015, Kyle Bass filed IPRs against a patent on Shire's Gattex and against a patent on Celgene's Thalomid.In covering this in the post Bass Expands Drug Patent Fight as Celgene, Shire Make Five , Bloomberg made some statements which require clarification.As to the text --Bass said he’s not targeting the entire drug industry and won’t accept settlement payments in order to drop the challenges --, the Engellener article [below] notes that in the… [read post]
4 Nov 2007, 7:03 pm
Celgene Corporation et al. v. [read post]
3 Aug 2015, 10:00 pm
Celgene Corp. [read post]
8 Oct 2020, 9:45 am
The prescription medications targeted by the lawmakers included “Celgene and Bristol Myers Squibb’s Revlimid cancer treatment, which saw its price hiked 23 times since 2005, and Teva’s multiple sclerosis drug Copaxone, which went up in price 27 times since 2007,” reported the independent, nonpartisan Kaiser Health News service. [read post]
7 Nov 2019, 8:10 pm
Notable advances include Takeda (up 142% based in part on its Shire acquisition, and jumping in the rankings from 23rd to 17th Q4 2018 – Q1 2019), with several other companies showing robust growth (including Celgene Corp., 37%; Novo Nordisk AS, 17%; Novartis AG, 14%; and Merck KGa, 13%; Hoffmann-La Roche, 12.7%). [read post]
11 Nov 2019, 9:55 am
[Celgene Petition Rehearing]. [read post]
8 Nov 2021, 4:39 am
Celgene Corp. v. [read post]
11 Oct 2015, 9:38 pm
October 12, 2015 - "Hedge Fund IPR Challenges to Pharma Patents: Latest Developments and Strategies to Strengthen Patents -- Lessons From PTAB Denial of Acorda Therapeutics IPR, Celgene's Sanctions Motion, and More" (Strafford) - 1:00 to 2:30 pm (EDT) October 13, 2015 - Post-Grant Practice Roundtable Discussion (George Washington Law School) - George Washington University Law School October 13, 2015 - Patent Quality Chat webinar series (U.S. [read post]
10 Feb 2019, 9:38 pm
February 11, 2019 - "The Next Billion-Dollar Acquisition in Pharma -- A Forward-Looking Patent Analysis on Bristol-Myers Squibb Acquiring Celgene" (LexisNexis) - 2:00 pm (ET) February 12, 2019 - "Biotech Patents and Section 101 Rejections: Meeting Patent Eligibility Requirements -- Leveraging Recent Decisions and USPTO Guidance to Overcome Rejections" (Strafford) - 1:00 to 2:30 pm (EST) February 14, 2019 - "Section 112 Issues in IPR Proceedings: Using Section 112 as… [read post]